Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
VIR Vir Biotechnology Inc
- Stocks
- Healthcare
- NASDAQ: VIR
Price (delayed)
$5.05
Market cap
$698.1M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.22
Enterprise value
$424.55M
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are
Highlights
The debt has contracted by 19% YoY and by 2.2% from the previous quarter
VIR's revenue has plunged by 74% YoY and by 72% from the previous quarter
The company's gross profit has shrunk by 74% YoY and by 73% QoQ
Key stats
What are the main financial stats of VIR
Market
Valuations
Earnings
Shares outstanding
138.24M
Market cap
$698.1M
Enterprise value
$424.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.66
Price to sales (P/S)
33.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.35
Revenue
$20.86M
Gross profit
$20.08M
Operating income
-$646.63M
Net income
-$577.65M
EBIT
-$579.05M
EBITDA
-$561.22M
Free cash flow
-$419.02M
Per share
Balance sheet
Liquidity
EPS
-$4.22
EPS diluted
-$4.22
Free cash flow per share
-$3.05
Book value per share
$7.61
Revenue per share
$0.15
TBVPS
$9.33
Total assets
$1.31B
Total liabilities
$263.91M
Debt
$88.17M
Equity
$1.04B
Working capital
$794.92M
Debt to equity
0.08
Current ratio
6.79
Quick ratio
6.48
Net debt/EBITDA
0.49
Margins
Efficiency
Dividend
EBITDA margin
-2,690.3%
Gross margin
96.2%
Net margin
-2,769%
Operating margin
-3,099.7%
Return on assets
-39.3%
Return on equity
-47.5%
Return on invested capital
-52.6%
Return on capital employed
-49.5%
Return on sales
-2,775.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VIR stock price
How has the Vir Biotechnology stock price performed over time
Intraday
-2.32%
1 week
0%
1 month
2.23%
1 year
-43.26%
YTD
-31.2%
QTD
-22.07%
Financial performance
How have Vir Biotechnology's revenue and profit performed over time
Revenue
$20.86M
Gross profit
$20.08M
Operating income
-$646.63M
Net income
-$577.65M
Gross margin
96.2%
Net margin
-2,769%
VIR's revenue has plunged by 74% YoY and by 72% from the previous quarter
The company's gross profit has shrunk by 74% YoY and by 73% QoQ
The net income has declined by 11% since the previous quarter and by 7% year-on-year
The company's operating income fell by 10% QoQ and by 4.1% YoY
Price vs fundamentals
How does VIR's price correlate with its fundamentals
Growth
What is Vir Biotechnology's growth rate over time
Valuation
What is Vir Biotechnology stock price valuation
P/E
N/A
P/B
0.66
P/S
33.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.35
The EPS has declined by 10% since the previous quarter and by 5% year-on-year
VIR's price to book (P/B) is 78% lower than its 5-year quarterly average of 3.1 and 15% lower than its last 4 quarters average of 0.8
Vir Biotechnology's equity has decreased by 33% YoY and by 9% from the previous quarter
VIR's revenue has plunged by 74% YoY and by 72% from the previous quarter
The price to sales (P/S) is 61% higher than the last 4 quarters average of 21.1 and 49% higher than the 5-year quarterly average of 22.9
Efficiency
How efficient is Vir Biotechnology business performance
Vir Biotechnology's return on equity has decreased by 46% YoY and by 22% QoQ
Vir Biotechnology's return on assets has decreased by 46% YoY and by 20% QoQ
The return on invested capital has declined by 45% year-on-year and by 29% since the previous quarter
Dividends
What is VIR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VIR.
Financial health
How did Vir Biotechnology financials performed over time
VIR's quick ratio is down by 48% year-on-year and by 22% since the previous quarter
The current ratio has contracted by 47% YoY and by 22% from the previous quarter
The debt is 92% less than the equity
Vir Biotechnology's equity has decreased by 33% YoY and by 9% from the previous quarter
The debt has contracted by 19% YoY and by 2.2% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.